| abstract |
The present invention provides methods for treating metabolic diseases and disorders using FGF21 polypeptides. Metabolic diseases or disorders are type 1 diabetes, obesity, dyslipidemia, elevated blood glucose level, elevated insulin level, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease . A method of treating metabolic disorders, wherein a therapeutically effective amount of (a) an isolated human FGF21 polypeptide or (b) an FGF21 variant polypeptide is administered to a subject in need of treatment. Administering. [Selection] Figure 1 |